Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Auras

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Auras. Displaying page 1 of 1.
    EudraCT Number: 2011-006207-36 Sponsor Protocol Number: 19122011 Start Date*: 2012-09-27
    Sponsor Name:Proreo Pharma Innovation AG
    Full Title: A multi centre, double blind, randomised, placebo controlled crossover study to evaluate the efficacy and tolerability of picotamide in the prophylaxis of migraine in patients presenting with migra...
    Medical condition: Migraine with aura, ICD-10NA G43.1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2007-000897-21 Sponsor Protocol Number: N01280 Start Date*: 2008-02-05
    Sponsor Name:UCB, Inc.
    Full Title: A multi-center, double-blind, historical control, randomized conversion to monotherapy study with Keppra XR for treatment of partial onset seizures
    Medical condition: partial onset seizures
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039911 Seizures (incl subtypes) HLGT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2009-013701-34 Sponsor Protocol Number: VMMET009 Start Date*: 2011-09-01
    Sponsor Name:Hospital of the University of Munich
    Full Title: Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo- controlled trial
    Medical condition: vestibular migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-001288-18 Sponsor Protocol Number: 16-API-01 Start Date*: 2019-01-08
    Sponsor Name:CHU de Nice
    Full Title: ASIC channels and migraine disorders - Proof of concept study on the efficacy of Amiloride in prophylaxis of Migraine with Aura - APAM study
    Medical condition: Migraine with aura
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000144-14 Sponsor Protocol Number: N01276 Start Date*: 2008-07-14
    Sponsor Name:UCB Inc
    Full Title: An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to...
    Medical condition: Partial onset seizures with or without secondary generalization.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015037 Epilepsy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010721-39 Sponsor Protocol Number: NXN-188-202 Start Date*: 2009-04-27
    Sponsor Name:Peer Tfelt-Hansen
    Full Title: A phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks with Aura
    Medical condition: MIgraine with aura
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027607 Migraine with aura LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000145-58 Sponsor Protocol Number: N01306 Start Date*: 2008-07-11
    Sponsor Name:UCB Pharma S.A.
    Full Title: An international, double-blind, randomized, multi-center, parallel group, historical-control conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to...
    Medical condition: Partial onset seizures with or without secondary generalization.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015037 Epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) HU (Prematurely Ended) FI (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005689-40 Sponsor Protocol Number: COL-MIG-302 Start Date*: 2016-10-18
    Sponsor Name:CoLucid Pharmaceuticals, Inc.
    Full Title: A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A randomized, double-blind, placebo-controlled parallel group study (SPARTAN)
    Medical condition: acute migraine
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10066635 Acute migraine LLT
    19.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    19.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    19.0 10029205 - Nervous system disorders 10027599 Migraine PT
    19.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002470-27 Sponsor Protocol Number: 3101-312-002 Start Date*: 2021-05-12
    Sponsor Name:Allergan Limited
    Full Title: A PHASE 3, MULTICENTER, OPEN-LABEL 52-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH CHRONIC OR EPISODI...
    Medical condition: Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    21.1 10029205 - Nervous system disorders 10066636 Chronic migraine LLT
    22.0 10029205 - Nervous system disorders 10082019 Episodic migraine LLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Ongoing) CZ (Trial now transitioned) SE (Completed) HU (Ongoing) DK (Trial now transitioned) NL (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005246-15 Sponsor Protocol Number: BHV3000-315 Start Date*: 2022-08-23
    Sponsor Name:Biohaven Pharmaceuticals Holding Company Limited
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to <18 years of age
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005674-37 Sponsor Protocol Number: COL-MIG-305(H8H-CD-LAHL) Start Date*: 2016-11-01
    Sponsor Name:Eli Lilly and Company
    Full Title: An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)
    Medical condition: acute migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10066635 Acute migraine LLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005239-22 Sponsor Protocol Number: BHV3000-404 Start Date*: 2022-06-20
    Sponsor Name:Biohaven Pharmaceuticals Holding Company Limited
    Full Title: A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Ongoing) SE (Ongoing) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003761-18 Sponsor Protocol Number: BHV3000-312 Start Date*: 2022-01-20
    Sponsor Name:Biohaven Pharmaceuticals Inc.
    Full Title: Phase 3, multicenter, open-label study to assess the long-term safety and tolerability of rimegepant for the acute treatment of migraine (with or without aura) in children and adolescents ≥ 6 to < ...
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    21.1 10029205 - Nervous system disorders 10066635 Acute migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003517-35 Sponsor Protocol Number: BHV3000-311 Start Date*: 2021-05-05
    Sponsor Name:Pfizer, Inc.
    Full Title: Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in childr...
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    21.1 10029205 - Nervous system disorders 10066635 Acute migraine LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Ongoing) PL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:45:58 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA